Form 4: RA Capital Reduces Vor Biopharma Stake by 400K Shares

RA Capital Management and its affiliates reported multiple sales of Vor Biopharma common stock in late October 2025, significantly reducing their beneficial ownership.

Summary

• RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev M. Shah, identified as Directors and 10% Owners, reported sales of Vor Biopharma Inc. common stock.
• Transactions occurred on October 28, 29, and 30, 2025.
• A total of 400,408 shares of common stock were sold across four separate transactions.
• Weighted average sale prices ranged from $25.12 to $28.18 per share.
• Following these transactions, the beneficial ownership of RA Capital Healthcare Fund LP decreased to 779,652 shares.
• The reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 3

Explanation: The substantial selling of shares by a major institutional investor and director, RA Capital Management, L.P., indicates a negative sentiment or a strategic decision to reduce exposure to Vor Biopharma Inc.

Negatives

• Significant insider selling by a major institutional investor and director (RA Capital Management, L.P. and its affiliates) suggests a potential lack of confidence or a strategic portfolio adjustment.
• The sales occurred over multiple days, indicating a systematic reduction in their stake.
• The total of 400,408 shares sold represents a substantial portion of their previous holdings.

Future Outlook

NA

Management Comments

• RA Capital Management, L.P., RA Capital Management GP, LLC, Dr. Peter Kolchinsky, and Mr. Rajeev Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.

Industry Context

NA

Related Party Transactions

• Sales of common stock by RA Capital Management, L.P. and its affiliates, who are 10% owners and have directors on the board of Vor Biopharma Inc.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal regarding the company's future prospects or valuation, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The substantial divestment of 400,408 shares by RA Capital Management, L.P., a significant institutional investor and director, signals a lack of confidence or a strategic move away from Vor Biopharma Inc. This insider selling activity often precedes periods of underperformance and suggests that the stock may face downward pressure. Investors should consider this a strong negative signal.

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Sales, Stock Transactions, Beneficial Ownership, Form 4